Amazon Biotech: protocol approved for phase 1/ 2 trial of HIV therapy

By Lisa Kerner

Charlotte, N.C., June 22 - Amazon Biotech, Inc. said, following its meeting with the Food and Drug Administration, the company can move forward with its phase 1/ 2 trial of its proprietary AMZ0026 therapy in HIV-positive patients.

The safety, immunological and antiviral effects of AMZ0026 will be studied in a double-blind, placebo-controlled trial of 32 non-symptomatic HIV subjects who have not been treated with Highly Active Anti-Retroviral Therapy (HAART).

The six-month study will monitor T Cell increases and HIV plasma viral load decreases, according to a company news release.

Amazon is a natural plant pharmaceutical drug company located in New York City.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.